Search

Your search keyword '"Gower, E"' showing total 118 results
Start Over Author "Gower, E"
118 results on '"Gower, E"'

1. Pharmacological characterisation of GSK3335103, an oral αvβ6 integrin small molecule RGD-mimetic inhibitor for the treatment of fibrotic disease

Author

Wilkinson, Alex L., John, Alison E., Barrett, John W., Gower, E., Morrison, Valerie S., Man, Yim, Pun, K. Tao, Roper, James A., Luckett, Jeni C., Borthwick, Lee A., Barksby, Ben S., Burgoyne, Rachel A., Barnes, Rory, Fisher, Andrew J., Procopiou, Panayiotis A., Hatley, Richard J.D., Barrett, Tim N., Marshall, Richard P., Macdonald, Simon J.F., Jenkins, R. Gisli, and Slack, Robert J.

Published
2021
Full Text
View/download PDF

2. Harnessing photography and image recognition technology to aid in the elimination of trachoma

Author

Gower, E., West, S.K., Harding-Esch, E., and Jimenez, C.

Abstract

Significant progress has been made to reduce the global burden of trachoma in recent years. Since 2002, the number of people at risk has reduced by 92%, from 1.5 billion to 124 million. The number of people estimated to require surgery to treat trachomatous trichiasis (TT), the late blinding stage of trachoma, has reduced by 76% in the same period: from 7.6 million to 1.8 million.

Published
2022
Full Text
View/download PDF

3. The present and future disease burden of hepatitis C virus (HCV) infections with todayʼs treatment paradigm – volume 2

Author

Hatzakis, A., Chulanov, V., Gadano, A. C., Bergin, C., Ben-Ari, Z., Mossong, J., Schréter, I., Baatarkhuu, O., Acharya, S., Aho, I., Anand, A. C., Andersson, M. I., Arendt, V., Arkkila, P., Barclay, K., Bessone, F., Blach, S., Blokhina, N., Brunton, C. R., Choudhuri, G., Cisneros, L., Croes, E. A., Dahgwahdorj, Y. A., Dalgard, O., Daruich, J. R., Dashdorj, N. R., Davaadorj, D., de Knegt, R. J., de Vree, M., Estes, C., Flisiak, R., Gane, E., Gower, E., Halota, W., Henderson, C., Hoffmann, P., Hornell, J., Houlihan, D., Hrusovsky, S., Jarčuška, P., Kershenobich, D., Kostrzewska, K., Kristian, P., Leshno, M., Lurie, Y., Mahomed, A., Mamonova, N., Mendez-Sanchez, N., Norris, S., Nurmukhametova, E., Nymadawa, P., Oltman, M., Oyunbileg, J., Oyunsuren, Ts., Papatheodoridis, G., Pimenov, N., Prabdial-Sing, N., Prins, M., Radke, S., Rakhmanova, A., Razavi-Shearer, K., Reesink, H. W., Ridruejo, E., Safadi, R., Sagalova, O., Avila, Sanchez J. F., Sanduijav, R., Saraswat, V., Seguin-Devaux, C., Shah, S. R., Shestakova, I., Shevaldin, A., Shibolet, O., Silva, M. O., Sokolov, S., Sonderup, M., Souliotis, K., Spearman, C. W., Staub, T., Stedman, C., Strebkova, E. A., Struck, D., Sypsa, V., Tomasiewicz, K., Undram, L., van der Meer, A. J., van Santen, D., Veldhuijzen, I., Villamil, F. G., Willemse, S., Zuckerman, E., Zuure, F. R., Puri, P., and Razavi, H.

Published
2015
Full Text
View/download PDF

4. Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2

Author

Gane, E., Kershenobich, D., Seguin-Devaux, C., Kristian, P., Aho, I., Dalgard, O., Shestakova, I., Nymadawa, P., Blach, S., Acharya, S., Anand, A. C., Andersson, M. I., Arendt, V., Arkkila, P., Baatarkhuu, O., Barclay, K., Ben-Ari, Z., Bergin, C., Bessone, F., Blokhina, N., Brunton, C. R., Choudhuri, G., Chulanov, V., Cisneros, L., Croes, E. A., Dahgwahdorj, Y. A., Daruich, J. R., Dashdorj, N. R., Davaadorj, D., de Knegt, R. J., de Vree, M., Gadano, A. C., Gower, E., Halota, W., Hatzakis, A., Henderson, C., Hoffmann, P., Hornell, J., Houlihan, D., Hrusovsky, S., Jarčuška, P., Kostrzewska, K., Leshno, M., Lurie, Y., Mahomed, A., Mamonova, N., Mendez-Sanchez, N., Mossong, J., Norris, S., Nurmukhametova, E., Oltman, M., Oyunbileg, J., Oyunsuren, Ts., Papatheodoridis, G., Pimenov, N., Prins, M., Puri, P., Radke, S., Rakhmanova, A., Razavi, H., Razavi-Shearer, K., Reesink, H. W., Ridruejo, E., Safadi, R., Sagalova, O., Avila, Sanchez J. F., Sanduijav, R., Saraswat, V., Schréter, I., Shah, S. R., Shevaldin, A., Shibolet, O., Silva, M. O., Sokolov, S., Sonderup, M., Souliotis, K., Spearman, C. W., Staub, T., Stedman, C., Strebkova, E. A., Struck, D., Sypsa, V., Tomasiewicz, K., Undram, L., van der Meer, A. J., van Santen, D., Veldhuijzen, I., Villamil, F. G., Willemse, S., Zuckerman, E., Zuure, F. R., Prabdial-Sing, N., Flisiak, R., and Estes, C.

Published
2015
Full Text
View/download PDF

5. Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2

Author

Saraswat, V., Norris, S., de Knegt, R. J., Avila, Sanchez J. F., Sonderup, M., Zuckerman, E., Arkkila, P., Stedman, C., Acharya, S., Aho, I., Anand, A. C., Andersson, M. I., Arendt, V., Baatarkhuu, O., Barclay, K., Ben-Ari, Z., Bergin, C., Bessone, F., Blach, S., Blokhina, N., Brunton, C. R., Choudhuri, G., Chulanov, V., Cisneros, L., Croes, E. A., Dahgwahdorj, Y. A., Dalgard, O., Daruich, J. R., Dashdorj, N. R., Davaadorj, D., de Vree, M., Estes, C., Flisiak, R., Gadano, A. C., Gane, E., Halota, W., Hatzakis, A., Henderson, C., Hoffmann, P., Hornell, J., Houlihan, D., Hrusovsky, S., Jarčuška, P., Kershenobich, D., Kostrzewska, K., Kristian, P., Leshno, M., Lurie, Y., Mahomed, A., Mamonova, N., Mendez-Sanchez, N., Mossong, J., Nurmukhametova, E., Nymadawa, P., Oltman, M., Oyunbileg, J., Oyunsuren, Ts., Papatheodoridis, G., Pimenov, N., Prabdial-Sing, N., Prins, M., Puri, P., Radke, S., Rakhmanova, A., Razavi, H., Razavi-Shearer, K., Reesink, H. W., Ridruejo, E., Safadi, R., Sagalova, O., Sanduijav, R., Schréter, I., Seguin-Devaux, C., Shah, S. R., Shestakova, I., Shevaldin, A., Shibolet, O., Sokolov, S., Souliotis, K., Spearman, C. W., Staub, T., Strebkova, E. A., Struck, D., Tomasiewicz, K., Undram, L., van der Meer, A. J., van Santen, D., Veldhuijzen, I., Villamil, F. G., Willemse, S., Zuure, F. R., Silva, M. O., Sypsa, V., and Gower, E.

Published
2015
Full Text
View/download PDF

6. Strategies to manage hepatitis C virus (HCV) disease burden

Author

Wedemeyer, H., Duberg, A. S., Buti, M., Rosenberg, W. M., Frankova, S., Esmat, G., Örmeci, N., Van Vlierberghe, H., Gschwantler, M., Akarca, U., Aleman, S., Balk, İ., Berg, T., Bihl, F., Bilodeau, M., Blasco, A. J., Brandão Mello, C. E., Bruggmann, P., Calinas, F., Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cornberg, M., Cramp, M. E., Dore, G. J., Doss, W., El-Sayed, M. H., Ergör, G., Estes, C., Falconer, K., Félix, J., Ferraz, M. L. G., Ferreira, P. R., García-Samaniego, J., Gerstoft, J., Giria, J. A., Gonçales, F. L., Jr, Guimarães Pessôa, M., Hézode, C., Hindman, S. J., Hofer, H., Husa, P., Idilman, R., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W., Lavanchy, D., Lázaro, P., Marinho, R. T., Marotta, P., Mauss, S., Mendes Correa, M. C., Moreno, C., Müllhaupt, B., Myers, R. P., Nemecek, V., vrehus, A. L. H., Parkes, J., Peltekian, K. M., Ramji, A., Razavi, H., Reis, N., Roberts, S. K., Roudot-Thoraval, F., Ryder, S. D., Sarmento-Castro, R., Sarrazin, C., Semela, D., Sherman, M., Shiha, G. E., Sperl, J., Stärkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., Van Damme, P., van Thiel, I., Vandijck, D., Vogel, W., Waked, I., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Negro, F., Sievert, W., and Gower, E.

Published
2014
Full Text
View/download PDF

7. The present and future disease burden of hepatitis C virus (HCV) infection with todayʼs treatment paradigm

Author

Razavi, H., Waked, I., Sarrazin, C., Myers, R. P., Idilman, R., Calinas, F., Vogel, W., Mendes Correa, M. C., Hézode, C., Lázaro, P., Akarca, U., Aleman, S., Balk, İ., Berg, T., Bihl, F., Bilodeau, M., Blasco, A. J., Brandão Mello, C. E., Bruggmann, P., Buti, M., Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cramp, M. E., Dore, G. J., Doss, W., Duberg, A. S., El-Sayed, M. H., Ergör, G., Esmat, G., Falconer, K., Félix, J., Ferraz, M. L. G., Ferreira, P. R., Frankova, S., García-Samaniego, J., Gerstoft, J., Giria, J. A., Gonçales, F. L., Jr, Gower, E., Gschwantler, M., Guimarães Pessôa, M., Hindman, S. J., Hofer, H., Husa, P., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W., Lavanchy, D., Marinho, R. T., Marotta, P., Mauss, S., Moreno, C., Murphy, K., Negro, F., Nemecek, V., Örmeci, N., vrehus, A. L. H., Parkes, J., Pasini, K., Peltekian, K. M., Ramji, A., Reis, N., Roberts, S. K., Rosenberg, W. M., Roudot-Thoraval, F., Ryder, S. D., Sarmento-Castro, R., Semela, D., Sherman, M., Shiha, G. E., Sievert, W., Sperl, J., Stärkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., Van Damme, P., van Thiel, I., Van Vlierberghe, H., Vandijck, D., Wedemeyer, H., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Cornberg, M., Müllhaupt, B., and Estes, C.

Published
2014
Full Text
View/download PDF

8. Historical epidemiology of hepatitis C virus (HCV) in selected countries

Author

Bruggmann, P., Berg, T., vrehus, A. L. H., Moreno, C., Brandão Mello, C. E., Roudot-Thoraval, F., Marinho, R. T., Sherman, M., Ryder, S. D., Sperl, J., Akarca, U., Balk, İ., Bihl, F., Bilodeau, M., Blasco, A. J., Buti, M., Calinas, F., Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cornberg, M., Cramp, M. E., Dore, G. J., Doss, W., Duberg, A. S., El-Sayed, M. H., Ergör, G., Esmat, G., Estes, C., Falconer, K., Félix, J., Ferraz, M. L. G., Ferreira, P. R., Frankova, S., García-Samaniego, J., Gerstoft, J., Giria, J. A., Gonçales, F. L., Jr, Gower, E., Gschwantler, M., Guimarães Pessôa, M., Hézode, C., Hofer, H., Husa, P., Idilman, R., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W., Lavanchy, D., Lázaro, P., Marotta, P., Mauss, S., Mendes Correa, M. C., Müllhaupt, B., Myers, R. P., Negro, F., Nemecek, V., Örmeci, N., Parkes, J., Peltekian, K. M., Ramji, A., Razavi, H., Reis, N., Roberts, S. K., Rosenberg, W. M., Sarmento-Castro, R., Sarrazin, C., Semela, D., Shiha, G. E., Sievert, W., Stärkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., van Thiel, I., Van Vlierberghe, H., Vandijck, D., Vogel, W., Waked, I., Wedemeyer, H., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Van Damme, P., Aleman, S., and Hindman, S. J.

Published
2014
Full Text
View/download PDF

9. Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis

Author

Platt, L, French, CE, McGowan, CR, Sabin, K, Gower, E, Trickey, A, McDonald, B, Ong, J, Stone, J, Easterbrook, P, Vickerman, P, Platt, L, French, CE, McGowan, CR, Sabin, K, Gower, E, Trickey, A, McDonald, B, Ong, J, Stone, J, Easterbrook, P, and Vickerman, P

Abstract

Globally, in 2017 35 million people were living with HIV (PLHIV) and 257 million had chronic HBV infection (HBsAg positive). The extent of HIV-HBsAg co-infection is unknown. We undertook a systematic review to estimate the global burden of HBsAg co-infection in PLHIV. We searched MEDLINE, Embase and other databases for published studies (2002-2018) measuring prevalence of HBsAg among PLHIV. The review was registered with PROSPERO (#CRD42019123388). Populations were categorized by HIV-exposure category. The global burden of co-infection was estimated by applying regional co-infection prevalence estimates to UNAIDS estimates of PLHIV. We conducted a meta-analysis to estimate the odds of HBsAg among PLHIV compared to HIV-negative individuals. We identified 506 estimates (475 studies) of HIV-HBsAg co-infection prevalence from 80/195 (41.0%) countries. Globally, the prevalence of HIV-HBsAg co-infection is 7.6% (IQR 5.6%-12.1%) in PLHIV, or 2.7 million HIV-HBsAg co-infections (IQR 2.0-4.2). The greatest burden (69% of cases; 1.9 million) is in sub-Saharan Africa. Globally, there was little difference in prevalence of HIV-HBsAg co-infection by population group (approximately 6%-7%), but it was slightly higher among people who inject drugs (11.8% IQR 6.0%-16.9%). Odds of HBsAg infection were 1.4 times higher among PLHIV compared to HIV-negative individuals. There is therefore, a high global burden of HIV-HBsAg co-infection, especially in sub-Saharan Africa. Key prevention strategies include infant HBV vaccination, including a timely birth-dose. Findings also highlight the importance of targeting PLHIV, especially high-risk groups for testing, catch-up HBV vaccination and other preventative interventions. The global scale-up of antiretroviral therapy (ART) for PLHIV using a tenofovir-based ART regimen provides an opportunity to simultaneously treat those with HBV co-infection, and in pregnant women to also reduce mother-to-child transmission of HBV alongside HIV.

Published
2020

12. Pollution is Possible

Author

Gower, E, Sierra, MA, Gower, E, and Sierra, MA

Abstract

Research Background: The ‘9x5’ concept and title references the original exhibition of Impressionist works held at the Buxton Galleries in 1889 which included the work of key Australian Impressionist artists - Tom Roberts, Arthur Streeton, Frederick McCubbin and Charles Condor, all graduates from the National Gallery of Victoria Art School, the founding institution of the Victorian College of the Arts (VCA). The artworks of that 1889 exhibition were painted on cigar box lids and the title of the exhibition is derived from the dimensions of those works (9 by 5 inches). Research Contribution: All the artists in ‘9X5 Now Exhibition: Art 150’ are well-known contemporary practitioners, exhibiting nationally and internationally, and in major exhibitions and biennales. The exhibition marks the VCA as a key contributor to the cultural life of Melbourne, Victoria and Australia, is made up of the work of current staff, former staff and former students of the Victorian College of the Arts. Entry was only by direct invitation from the curator, preeminent artist Elizabeth Gower. Research Significance: The exhibition is one of a suite of exhibitions and public programs through autumn-winter 2017 (including artist talks, tours and a one-day symposium) that mark the 150th anniversary of the Victorian College of the Arts. As the only exhibition to bring together those that have a significant professional relationship with the VCA, either as staff, former staff or former students, the exhibition captures and reflects to a contemporary audience the pivotal role that tertiary art institutions play in the creation of culture, and cultural capital, in Australia.

Published
2017

14. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2

Author

Hatzakis, A. Chulanov, V. Gadano, A. C. Bergin, C. and Ben-Ari, Z. Mossong, J. Schreter, I. Baatarkhuu, O. and Acharya, S. Aho, I. Anand, A. C. Andersson, M. I. and Arendt, V. Arkkila, P. Barclay, K. Bessone, F. Blach, S. and Blokhina, N. Brunton, C. R. Choudhuri, G. Cisneros, L. and Croes, E. A. Dahgwahdorj, Y. A. Dalgard, O. Daruich, J. R. Dashdorj, N. R. Davaadorj, D. de Knegt, R. J. de Vree, M. Estes, C. Flisiak, R. Gane, E. Gower, E. and Halota, W. Henderson, C. Hoffmann, P. Hornell, J. and Houlihan, D. Hrusovsky, S. Jarcuska, P. Kershenobich, D. and Kostrzewska, K. Kristian, P. Leshno, M. Lurie, Y. and Mahomed, A. Mamonova, N. Mendez-Sanchez, N. Norris, S. and Nurmukhametova, E. Nymadawa, P. Oltman, M. Oyunbileg, J. and Oyunsuren, Ts. Papatheodoridis, G. Pimenov, N. and Prabdial-Sing, N. Prins, M. Radke, S. Rakhmanova, A. and Razavi-Shearer, K. Reesink, H. W. Ridruejo, E. Safadi, R. and Sagalova, O. Sanchez Avila, J. F. Sanduijav, R. and Saraswat, V. Seguin-Devaux, C. Shah, S. R. Shestakova, I. and Shevaldin, A. Shibolet, O. Silva, M. O. Sokolov, S. and Sonderup, M. Souliotis, K. Spearman, C. W. Staub, T. and Stedman, C. Strebkova, E. A. Struck, D. Sypsa, V. and Tomasiewicz, K. Undram, L. van der Meer, A. J. van Santen, D. Veldhuijzen, I. Villamil, F. G. Willemse, S. and Zuckerman, E. Zuure, F. R. Puri, P. Razavi, H.

Abstract

Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 countries to quantify and characterize the viremic population, as well as estimate the number of new infections and HCV related deaths from 2013 to 2030. Expert consensus was used to determine current treatment levels and outcomes in each country. In most countries, viremic prevalence has already peaked. In every country studied, prevalence begins to decline before 2030, when current treatment levels were held constant. In contrast, cases of advanced liver disease and liver related deaths will continue to increase through 2030 in most countries. The current treatment paradigm is inadequate if large reductions in HCV related morbidity and mortality are to be achieved.

Published
2015

15. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2

Author

Saraswat, V. Norris, S. de Knegt, R. J. Sanchez Avila, J. F. and Sonderup, M. Zuckerman, E. Arkkila, P. Stedman, C. and Acharya, S. Aho, I. Anand, A. C. Andersson, M. I. and Arendt, V. Baatarkhuu, O. Barclay, K. Ben-Ari, Z. and Bergin, C. Bessone, F. Blach, S. Blokhina, N. Brunton, C. R. Choudhuri, G. Chulanov, V. Cisneros, L. Croes, E. A. Dahgwahdorj, Y. A. Dalgard, O. Daruich, J. R. and Dashdorj, N. R. Davaadorj, D. de Vree, M. Estes, C. and Flisiak, R. Gadano, A. C. Gane, E. Halota, W. Hatzakis, A. Henderson, C. Hoffmann, P. Hornell, J. Houlihan, D. and Hrusovsky, S. Jarcuska, P. Kershenobich, D. Kostrzewska, K. Kristian, P. Leshno, M. Lurie, Y. Mahomed, A. and Mamonova, N. Mendez-Sanchez, N. Mossong, J. Nurmukhametova, E. Nymadawa, P. Oltman, M. Oyunbileg, J. Oyunsuren, Ts. and Papatheodoridis, G. Pimenov, N. Prabdial-Sing, N. Prins, M. Puri, P. Radke, S. Rakhmanova, A. Razavi, H. and Razavi-Shearer, K. Reesink, H. W. Ridruejo, E. Safadi, R. and Sagalova, O. Sanduijav, R. Schreter, I. Seguin-Devaux, C. Shah, S. R. Shestakova, I. Shevaldin, A. Shibolet, O. and Sokolov, S. Souliotis, K. Spearman, C. W. Staub, T. and Strebkova, E. A. Struck, D. Tomasiewicz, K. Undram, L. and van der Meer, A. J. van Santen, D. Veldhuijzen, I. Villamil, F. G. Willemse, S. Zuure, F. R. Silva, M. O. Sypsa, V. and Gower, E.

Abstract

Chronic hepatitis C virus (HCV) infection is a leading cause of liver related morbidity and mortality. In many countries, there is a lack of comprehensive epidemiological data that are crucial in implementing disease control measures as new treatment options become available. Published literature, unpublished data and expert consensus were used to determine key parameters, including prevalence, viremia, genotype and the number of patients diagnosed and treated. In this study of 15 countries, viremic prevalence ranged from 0.13% in the Netherlands to 2.91% in Russia. The largest viremic populations were in India (8666000 cases) and Russia (4162000 cases). In most countries, males had a higher rate of infections, likely due to higher rates of injection drug use (IDU). Estimates characterizing the infected population are critical to focus screening and treatment efforts as new therapeutic options become available.

Published
2015

16. Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2

Author

Gane, E. Kershenobich, D. Seguin-Devaux, C. Kristian, P. and Aho, I. Dalgard, O. Shestakova, I. Nymadawa, P. Blach, S. Acharya, S. Anand, A. C. Andersson, M. I. Arendt, V. and Arkkila, P. Baatarkhuu, O. Barclay, K. Ben-Ari, Z. and Bergin, C. Bessone, F. Blokhina, N. Brunton, C. R. and Choudhuri, G. Chulanov, V. Cisneros, L. Croes, E. A. and Dahgwahdorj, Y. A. Daruich, J. R. Dashdorj, N. R. Davaadorj, D. de Knegt, R. J. de Vree, M. Gadano, A. C. Gower, E. and Halota, W. Hatzakis, A. Henderson, C. Hoffmann, P. and Hornell, J. Houlihan, D. Hrusovsky, S. Jarcuska, P. and Kostrzewska, K. Leshno, M. Lurie, Y. Mahomed, A. and Mamonova, N. Mendez-Sanchez, N. Mossong, J. Norris, S. and Nurmukhametova, E. Oltman, M. Oyunbileg, J. Oyunsuren, Ts. and Papatheodoridis, G. Pimenov, N. Prins, M. Puri, P. and Radke, S. Rakhmanova, A. Razavi, H. Razavi-Shearer, K. and Reesink, H. W. Ridruejo, E. Safadi, R. Sagalova, O. and Sanchez Avila, J. F. Sanduijav, R. Saraswat, V. Schreter, I. and Shah, S. R. Shevaldin, A. Shibolet, O. Silva, M. O. and Sokolov, S. Sonderup, M. Souliotis, K. Spearman, C. W. and Staub, T. Stedman, C. Strebkova, E. A. Struck, D. Sypsa, V. Tomasiewicz, K. Undram, L. van der Meer, A. J. van Santen, D. Veldhuijzen, I. Villamil, F. G. Willemse, S. and Zuckerman, E. Zuure, F. R. Prabdial-Sing, N. Flisiak, R. and Estes, C.

Abstract

The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries, and the relative impact of two scenarios was considered: (i) increased treatment efficacy while holding the treated population constant and (ii) increased treatment efficacy and increased annual treated population. Increasing levels of diagnosis and treatment, in combination with improved treatment efficacy, were critical for achieving substantial reductions in disease burden. In most countries, the annual treated population had to increase several fold to achieve the largest reductions in HCV-related morbidity and mortality. This suggests that increased capacity for screening and treatment will be critical in many countries. Birth cohort screening is a helpful tool for maximizing resources. In most of the studied countries, the majority of patients were born between 1945 and 1985.

Published
2015

17. Feminist Colour-IN booklet (Australian edition)

Author

Kontturi, K, Donaldson, K, Gower, E, Mayhew, M, Deacon, D, Textaqueen, A, Fraser, V, Richardson, E, Qureshi,, L, Kontturi, K, Donaldson, K, Gower, E, Mayhew, M, Deacon, D, Textaqueen, A, Fraser, V, Richardson, E, and Qureshi,, L

Published
2016

19. Historical epidemiology of hepatitis C virus (HCV) in selected countries

Author

Bruggmann, P, Berg, T, Øvrehus, ALH, Moreno, C, Brandão Mello, CE, Roudot-Thoraval, F, Marinho, RT, Sherman, M, Ryder, SD, Sperl, J, Akarca, U, Balık, I, Bihl, F, Bilodeau, M, Blasco, AJ, Buti, M, Calinas, F, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cornberg, M, Cramp, ME, Dore, GJ, Doss, W, Duberg, AS, El-Sayed, MH, Ergör, G, Esmat, G, Estes, C, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, Frankova, S, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Gower, E, Gschwantler, M, Guimarães Pessôa, M, Hézode, C, Hofer, H, Husa, P, Idilman, R, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Lázaro, P, Marotta, P, Mauss, S, Mendes Correa, MC, Müllhaupt, B, Myers, RP, Negro, F, Nemecek, V, Örmeci, N, Parkes, J, Peltekian, KM, Ramji, A, Razavi, H, Reis, N, Roberts, SK, Rosenberg, WM, Sarmento-Castro, R, Sarrazin, C, Semela, D, Shiha, GE, Sievert, W, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, van Thiel, I, Van Vlierberghe, H, Vandijck, D, Vogel, W, Waked, I, Wedemeyer, H, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Van Damme, P, Aleman, S, Hindman, SJ, Bruggmann, P, Berg, T, Øvrehus, ALH, Moreno, C, Brandão Mello, CE, Roudot-Thoraval, F, Marinho, RT, Sherman, M, Ryder, SD, Sperl, J, Akarca, U, Balık, I, Bihl, F, Bilodeau, M, Blasco, AJ, Buti, M, Calinas, F, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cornberg, M, Cramp, ME, Dore, GJ, Doss, W, Duberg, AS, El-Sayed, MH, Ergör, G, Esmat, G, Estes, C, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, Frankova, S, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Gower, E, Gschwantler, M, Guimarães Pessôa, M, Hézode, C, Hofer, H, Husa, P, Idilman, R, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Lázaro, P, Marotta, P, Mauss, S, Mendes Correa, MC, Müllhaupt, B, Myers, RP, Negro, F, Nemecek, V, Örmeci, N, Parkes, J, Peltekian, KM, Ramji, A, Razavi, H, Reis, N, Roberts, SK, Rosenberg, WM, Sarmento-Castro, R, Sarrazin, C, Semela, D, Shiha, GE, Sievert, W, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, van Thiel, I, Van Vlierberghe, H, Vandijck, D, Vogel, W, Waked, I, Wedemeyer, H, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Van Damme, P, Aleman, S, and Hindman, SJ

Abstract

Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype, diagnosis and treatment were obtained through literature searches and expert consensus for 16 countries. For some countries, data from centralized registries were used to estimate diagnosis and treatment rates. Data for the number of liver transplants and the proportion attributable to HCV were obtained from centralized databases. Viremic prevalence estimates varied widely between countries, ranging from 0.3% in Austria, England and Germany to 8.5% in Egypt. The largest viremic populations were in Egypt, with 6,358,000 cases in 2008 and Brazil with 2,106,000 cases in 2007. The age distribution of cases differed between countries. In most countries, prevalence rates were higher among males, reflecting higher rates of injection drug use. Diagnosis, treatment and transplant levels also differed considerably between countries. Reliable estimates characterizing HCV-infected populations are critical for addressing HCV-related morbidity and mortality. There is a need to quantify the burden of chronic HCV infection at the national level.

Published
2014

20. Strategies to manage hepatitis C virus (HCV) disease burden

Author

Wedemeyer, H, Duberg, AS, Buti, M, Rosenberg, WM, Frankova, S, Esmat, G, Örmeci, N, Van Vlierberghe, H, Gschwantler, M, Akarca, U, Aleman, S, Balık, I, Berg, T, Bihl, F, Bilodeau, M, Blasco, AJ, Brandão Mello, CE, Bruggmann, P, Calinas, F, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cornberg, M, Cramp, ME, Dore, GJ, Doss, W, El-Sayed, MH, Ergör, G, Estes, C, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Guimarães Pessôa, M, Hézode, C, Hindman, SJ, Hofer, H, Husa, P, Idilman, R, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Lázaro, P, Marinho, RT, Marotta, P, Mauss, S, Mendes Correa, MC, Moreno, C, Müllhaupt, B, Myers, RP, Nemecek, V, Øvrehus, ALH, Parkes, J, Peltekian, KM, Ramji, A, Razavi, H, Reis, N, Roberts, SK, Roudot-Thoraval, F, Ryder, SD, Sarmento-Castro, R, Sarrazin, C, Semela, D, Sherman, M, Shiha, GE, Sperl, J, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, Van Damme, P, van Thiel, I, Vandijck, D, Vogel, W, Waked, I, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Negro, F, Sievert, W, Gower, E, Wedemeyer, H, Duberg, AS, Buti, M, Rosenberg, WM, Frankova, S, Esmat, G, Örmeci, N, Van Vlierberghe, H, Gschwantler, M, Akarca, U, Aleman, S, Balık, I, Berg, T, Bihl, F, Bilodeau, M, Blasco, AJ, Brandão Mello, CE, Bruggmann, P, Calinas, F, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cornberg, M, Cramp, ME, Dore, GJ, Doss, W, El-Sayed, MH, Ergör, G, Estes, C, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Guimarães Pessôa, M, Hézode, C, Hindman, SJ, Hofer, H, Husa, P, Idilman, R, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Lázaro, P, Marinho, RT, Marotta, P, Mauss, S, Mendes Correa, MC, Moreno, C, Müllhaupt, B, Myers, RP, Nemecek, V, Øvrehus, ALH, Parkes, J, Peltekian, KM, Ramji, A, Razavi, H, Reis, N, Roberts, SK, Roudot-Thoraval, F, Ryder, SD, Sarmento-Castro, R, Sarrazin, C, Semela, D, Sherman, M, Shiha, GE, Sperl, J, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, Van Damme, P, van Thiel, I, Vandijck, D, Vogel, W, Waked, I, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Negro, F, Sievert, W, and Gower, E

Abstract

The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.

Published
2014

21. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

Author

Razavi, H, Waked, I, Sarrazin, C, Myers, RP, Idilman, R, Calinas, F, Vogel, W, Mendes Correa, MC, Hézode, C, Lázaro, P, Akarca, U, Aleman, S, Balık, I, Berg, T, Bihl, F, Bilodeau, M, Blasco, AJ, Brandão Mello, CE, Bruggmann, P, Buti, M, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cramp, ME, Dore, GJ, Doss, W, Duberg, AS, El-Sayed, MH, Ergör, G, Esmat, G, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, Frankova, S, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Gower, E, Gschwantler, M, Guimarães Pessôa, M, Hindman, SJ, Hofer, H, Husa, P, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Marinho, RT, Marotta, P, Mauss, S, Moreno, C, Murphy, K, Negro, F, Nemecek, V, Örmeci, N, Øvrehus, ALH, Parkes, J, Pasini, K, Peltekian, KM, Ramji, A, Reis, N, Roberts, SK, Rosenberg, WM, Roudot-Thoraval, F, Ryder, SD, Sarmento-Castro, R, Semela, D, Sherman, M, Shiha, GE, Sievert, W, Sperl, J, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, Van Damme, P, van Thiel, I, Van Vlierberghe, H, Vandijck, D, Wedemeyer, H, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Cornberg, M, Müllhaupt, B, Estes, C, Razavi, H, Waked, I, Sarrazin, C, Myers, RP, Idilman, R, Calinas, F, Vogel, W, Mendes Correa, MC, Hézode, C, Lázaro, P, Akarca, U, Aleman, S, Balık, I, Berg, T, Bihl, F, Bilodeau, M, Blasco, AJ, Brandão Mello, CE, Bruggmann, P, Buti, M, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cramp, ME, Dore, GJ, Doss, W, Duberg, AS, El-Sayed, MH, Ergör, G, Esmat, G, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, Frankova, S, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Gower, E, Gschwantler, M, Guimarães Pessôa, M, Hindman, SJ, Hofer, H, Husa, P, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Marinho, RT, Marotta, P, Mauss, S, Moreno, C, Murphy, K, Negro, F, Nemecek, V, Örmeci, N, Øvrehus, ALH, Parkes, J, Pasini, K, Peltekian, KM, Ramji, A, Reis, N, Roberts, SK, Rosenberg, WM, Roudot-Thoraval, F, Ryder, SD, Sarmento-Castro, R, Semela, D, Sherman, M, Shiha, GE, Sievert, W, Sperl, J, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, Van Damme, P, van Thiel, I, Van Vlierberghe, H, Vandijck, D, Wedemeyer, H, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Cornberg, M, Müllhaupt, B, and Estes, C

Abstract

The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.

Published
2014

30. REEXAMINING MESOSIDERITE CLASSIFICATION SCHEMES.

Author

Gower, E. R. and Mayne, R. G.

Subjects
*METEORITES, *METALLOGRAPHY, *PLAGIOCLASE, *CLASSIFICATION, *PYROXENE
Abstract

Introduction: The formation of mesosiderites, a group of stony-iron meteorites, is complex; they are also historically understudied [1]. As a result, existing classification schemes have not been reexamined in several decades, despite the addition of numerous new mesosiderites to collections worldwide. Mesosiderites consist of roughly equal portions of Fe,Ni-metal and silicate material; however, current classification schemes are based on the plagioclase: pyroxene ratio and the degree of metamorphism or impact melting observed in their silicates [2,3], without consideration of the metal phase. The aim of this research is to: 1) increase the number of well characterized mesosiderites by examining a selection of understudied and/or unclassified examples, 2) establish whether metallography can be used to refine existing classification schemes to describe all portions of mesosiderites, and not only the silicates. Methodology: The Monnig Meteorite Collection database [4] was examined to identify mesosiderites that are either understudied (i.e., not present in published literature) and/or ungrouped (classified only as a mesosiderite but not into a petrologic or metamorphic type). Five mesosiderites were selected: North West Africa (NWA) 10882, NWA 2639, NWA 4230, NWA 1827, and Sahara (SAH) 98088. NWA 10882 (Fig. 1) only meets one of our criteria, as it has been classifed as an A2-type mesosiderite; however, as it has not been thoroughly characterized, the decision was made to still include it. Each sample was examined in hand specimen and thin section locations were chosen to include both silicate and metal portions of each mesosiderite, where possible. Two thin sections were made of each sample, with the exception of NWA 10882 where four sections were made. [ABSTRACT FROM AUTHOR]

Published
2022

31. Dishevelled Regulates the Metabolism of Amyloid Precursor Protein via Protein Kinase C/Mitogen-Activated Protein Kinase and c-Jun Terminal Kinase

Author

Mudher, A., primary, Chapman, S., additional, Richardson, J., additional, Asuni, A., additional, Gibb, G., additional, Pollard, C., additional, Killick, R., additional, Iqbal, T., additional, Raymond, L., additional, Varndell, I., additional, Sheppard, P., additional, Makoff, A., additional, Gower, E., additional, Soden, P. E., additional, Lewis, P., additional, Murphy, M., additional, Golde, T. E., additional, Rupniak, H. T., additional, Anderton, B. H., additional, and Lovestone, S., additional

Published
2001
Full Text
View/download PDF

35. Modeling of Six-Phase Reluctance DC Machine Using Finite Element Method.

Author

Rakgati, E. T., Tsalaile, T., and Gower, E.

Subjects
RELUCTANCE motors, FINITE element method, ELECTRICAL load, TORQUE, COMMUTATION (Electricity), ARMATURES
Abstract

In this paper a per phase equivalent circuit model of the reluctance DC machine is derived and investigated. The equivalent circuit parameters are determined through finite element analysis for both no-load and load conditions. The model is verified by comparing, amongst other things, the torque calculated from the determined equivalent circuit with the torque calculated by the finite element Maxwell stress tensor method and the measured static torque of a 35 kW reluctance DC machine drive. It is shown that the equivalent circuit parameters are severely affected by the phase current commutation under full load and the armature reaction effect. [ABSTRACT FROM AUTHOR]

Published
2011

40. Additional factors influencing sensitivity in the tetramethyl benzidine method for horseradish peroxidase neurohistochemistry.

Author

Mesulam, M M, Hegarty, E, Barbas, H, Carson, K A, Gower, E C, Knapp, A G, Moss, M B, and Mufson, E J

Abstract

In experiments that use horseradish peroxidase (HRP) and tetramethyl benzidine (TMB) for tracing neural connections, the activity of tissue-bound enzyme as well as the stability of the resultant reaction product are influenced by the duration of storage, the composition of the storage medium, the type of counterstaining and even the details of histological dehydration. Furthermore, the conditions for preserving HRP activity are very different from those necessary for preserving the stability of the tetramethyl benzidine (TMB) reaction product. Thus, tissue-bound HRP activity is stable at a neutral pH, while a much lower pH, around 3.3, is required for preserving the stability of the TMB reaction product. Recent evidence indicates that the stabilization bath in sodium nitroferricyanide that was previously recommended is not necessary. However, gradual dehydration of mounted sections is essential for long-term stability. Excessive counterstaining and excessive dehydration interfere with the detection of reaction product. These considerations are pertinent to experiments using free HRP as well as to those where the enzyme has been conjugated to wheat germ agglutinin.

Published
1980
Full Text
View/download PDF

41. On site : installations by Tom Arthur... [et al.].

Author

Arthur, T, Brown, J, Gower, E, Valamanesh, H, Arthur, T, Brown, J, Gower, E, and Valamanesh, H

Abstract

On site : installations by Tom Arthur... [et al.]. Catalogue of exhibition held at the Tasmanian School of Art Gallery, Sept. 4-Oct. 27, 1984 Includes bibliographical references Includes installations by Tom Arthur, Julie Brown, Elizabeth Gower and Hossein Valamanesh

42. On site : installations by Tom Arthur... [et al.].

Author

Arthur, T, Brown, J, Gower, E, Valamanesh, H, Arthur, T, Brown, J, Gower, E, and Valamanesh, H

Abstract

On site : installations by Tom Arthur... [et al.]. Catalogue of exhibition held at the Tasmanian School of Art Gallery, Sept. 4-Oct. 27, 1984 Includes bibliographical references Includes installations by Tom Arthur, Julie Brown, Elizabeth Gower and Hossein Valamanesh

43. Contemporary works from the University collection

Author

Anderson, L, Cleavin, B, Gaha, A, Gower, E, Johnstone, R, Keeling, D, Anderson, L, Cleavin, B, Gaha, A, Gower, E, Johnstone, R, and Keeling, D

Abstract

Contemporary works from the University collection Catalogue of exhibition held at Fine Arts Gallery, University of Tasmania, 10-30 June, 1988 Works by Lisa Anderson, Barry Cleavin, Anne Connors, Adrienne Gaha, Elizabeth Gower, Ruth Johnstone, David Keeling.

44. The Source : Micky Allan, Jonas Balsaitis, Peter Ellis, Keith Looby, Jan Murray, Geoff Parr, Stieg Persson, Robert Rooney, Vicki Varvaressos

Author

Gower, E and Gower, E

Abstract

The Source Catalogue of exhibitions held at the Centre for the Arts Gallery, Hunter street, Hobart 11 July - 3 August 1986 Curated by Elizabeth Gower Micky Allan, Jonas Balsaitis, Peter Ellis, Keith Looby, Jan Murray, Geoff Parr, Stieg Persson, Robert Rooney, Vicki Varvaressos Artists' preparatory studies, Australia

46. Installation and commissioning of the e/sup +//e/sup -/ injector for DAΦNE at Frascati

Author

Whitham, K., primary, Amankath, H., additional, Edighoffer, J., additional, Fleckner, K., additional, Gower, E., additional, Lyons, S., additional, Nett, D., additional, Palmer, D., additional, Sheppard, R., additional, Sutter, S., additional, Treas, P., additional, Zante, A., additional, Miller, R., additional, Boni, R., additional, Hsieh, H., additional, Sannibale, F., additional, Vescovi, M., additional, and Vignola, G., additional

Full Text
View/download PDF

47. 500 MW, 300 KW MODULATOR

Author

Anamkath, H., primary, Gower, E., additional, Kuenning, R., additional, Palmer, D., additional, Whitham, K., additional, and Zante, A., additional

Full Text
View/download PDF

49. Acoustic echo cancellation by minimising mutual information within sliding DFT window.

Author

Gower, E. S. and Hawksford, M. O. J.

Subjects
*ECHO, *ALGORITHMS, *LOUDSPEAKERS, *FOURIER transform infrared spectroscopy, *DISCRETE Fourier transforms, *INDEPENDENT component analysis
Abstract

An acoustic echo cancellation (AEC) algorithm based on minimising the mutual information between the loudspeaker and system output signals over a sliding discrete Fourier transform (DFT) window, for single AEC parameter estimation, is introduced. Unlike the conventional least-mean-square (LMS) systems, the proposed algorithm requires no double-talk detection (DTD) and its AEC parameter can be continually updated. Although it has been shown that independent component analysis (ICA) allows continual adaptation of the AEC parameters under DTD, current ICA-based algorithms estimate a filter of the same length as that of the LMS techniques. The sliding DFT window is utilised to facilitate adaptation of only one AEC parameter for deflation of the far-end signal, thereby greatly reducing the computational load. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

50. ECONOMIC IMPACT OF VISUAL IMPAIRMENT AND BLINDNESS IN THE UNITED STATES.

Author

Frick, K. D., Gower, E. W., Kempen, J. H., and Wolff, J. L.

Subjects
*ECONOMIC impact, *MEDICAL care, *HEALTH facilities, *VISION disorders, *BLINDNESS
Abstract

The article presents a study on the economic impact of excess demand for medical care and health utility due to visual impairment and blindness for people above 40 years in the U.S. Estimation of the relationship between visual impairment and blindness with medical expenses, informal care and health utility, including comorbidities and demographics, were done using data from the Medical Expenditure Panel Survey from 1996 to 2002. Studies reveal that visual impairment has a great effect on home care, which greatly costs the government.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results